CAIRO PHARMACEUTICALS
CPCI

EGX

Current Price
EGP
EGP (%)
Price Upon Recommendation
166.16 EGP
Target Price from Recommendation

172.50 EGP

+3.80%
Holding Period

From 1 to 3 months

Final Recommendation

Buy stock at the current price

Valid Until

May 16, 2025 at 11:59:59 PM

Risk Assessment

Medium

Confidence Score

75.00%

Potential Growth

18.50%

Investment Reason

CPCI demonstrates strong alignment with Egypt's growing infrastructure and real estate sectors, supported by EGX's bullish trends and steady foreign investment inflows.

Overview
Recent Performance

Outperformed EGX 30 Index with a 12% YTD gain, supported by strong Q1 earnings and sectoral tailwinds.

Economic Factors

Egypt's GDP growth (4.5% projected in 2024) and declining inflation boost consumer demand and sectoral activity.

Competitive Positioning

Strategic partnerships with government infrastructure projects and a diversified real estate portfolio enhance market resilience.

Analysis Summary

CPCI is poised to capitalize on Egypt's infrastructure boom and EGX's liquidity surge, offering attractive entry points amid favorable valuations.

Key Points
  • EGX 30's 9% YTD rally signals broad market optimism.
  • CPCI's P/E ratio (12.4x) below sector average (15.1x) indicates undervaluation.
  • Government infrastructure spending boosts real estate demand.
  • Technical indicators show bullish crossover in 50/200-day moving averages.
Recommendations